SYK Stock Chart & Stats
$5504.00
$120.94(2.10%)
At close: 4:00 PM EDT
$5504.00
$120.94(2.10%)
Day’s Range― - ―
52-Week Range$4,499.55 - $7,077.69
Previous CloseN/A
Volume264.00
Average Volume (3M)438.00
Market Cap
$2.10T
Enterprise Value$118.10B
Total Cash (Recent Filing)$3.27B
Total Debt (Recent Filing)$14.18B
Price to Earnings (P/E)30.9
Beta-0.13
Next Earnings
Feb 02, 2027EPS Estimate
94.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.45
Shares Outstanding383,573,060
10 Day Avg. Volume820
30 Day Avg. Volume438
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6,337.40Price Target Upside15.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)280.88
Revenue Forecast (FY)$510.68B
Bulls Say, Bears Say
Bulls Say
Organic Growth And Diversified DemandStryker is continuing to expand across multiple medical technology categories, reducing reliance on any single product line or procedure type. Broad organic growth, particularly in MedSurg and Neurotechnology, supports durable market-share gains and provides a stronger base for sustained revenue compounding.
Strong Margins And ProfitabilityHigh gross and operating margins indicate meaningful product differentiation, pricing power, and operating scale in Stryker’s core businesses. Margin expansion from operational efficiencies and expense discipline can support earnings growth, fund innovation, and improve resilience through variable procedure environments.
Innovation And Portfolio ExpansionStryker is extending its addressable market through acquisitions, robotics, and new surgical technologies rather than relying solely on existing implants. This active innovation and M&A strategy can strengthen customer relationships, broaden the portfolio, and create additional long-term growth avenues.
Bears Say
Hip And Knee SlowdownSlower hip and knee procedure growth directly limits demand for important orthopaedic products and may keep the segment near market growth instead of its historical outperformance. Affordability concerns, pre-authorization denials, and regional softness could prolong pressure over the next several quarters.
Orthopaedics Execution ChallengesExecution issues make the orthopaedics weakness more significant than an industry slowdown alone. Disruption from the cyber incident and SAP implementation, combined with slower new-product adoption, could delay recovery, weaken competitive momentum, and constrain near-term growth in a major franchise.
Supply And Guidance PressureThe reduced outlook signals that operational and market challenges are affecting the company’s near-term growth trajectory. Lingering vascular supply constraints and weaker orthopaedic trends may pressure revenue conversion, while a lower forecast reduces visibility into the pace of earnings progression.
Stryker News
SYK FAQ
What was Stryker Corporation’s price range in the past 12 months?
Stryker Corporation lowest stock price was $4499.55 and its highest was $7077.69 in the past 12 months.
What is Stryker Corporation’s market cap?
Stryker Corporation’s market cap is $2.10T.
When is Stryker Corporation’s upcoming earnings report date?
Stryker Corporation’s upcoming earnings report date is Feb 02, 2027 which is in 94 days.
How were Stryker Corporation’s earnings last quarter?
Stryker Corporation released its earnings results on Oct 29, 2026. The company reported $66.129 earnings per share for the quarter, missing the consensus estimate of $66.655 by -$0.526.
Is Stryker Corporation overvalued?
According to Wall Street analysts Stryker Corporation’s price is currently Undervalued.
Does Stryker Corporation pay dividends?
Stryker Corporation does not currently pay dividends.
What is Stryker Corporation’s EPS estimate?
Stryker Corporation’s EPS estimate is 94.44.
How many shares outstanding does Stryker Corporation have?
Stryker Corporation has 383,573,060 shares outstanding.
What happened to Stryker Corporation’s price movement after its last earnings report?
Stryker Corporation reported an EPS of $66.129 in its last earnings report, missing expectations of $66.655. Following the earnings report the stock price went down -1.799%.
Which hedge fund is a major shareholder of Stryker Corporation?
Currently, no hedge funds are holding shares in MX:SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6,337.40 (15.14% Upside)
$6,337.40 (15.14% Upside)
Blogger Sentiment
Bullish
MX:SYK Sentiment 85%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $2.2B over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 41%
Bearish news 59%
Bearish news 59%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.02%
12-Months-Change
Fundamentals
Return on Equity
15.61%
Trailing 12-Months
Asset Growth
0.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call was cautiously constructive but balanced. Stryker reported solid sales growth, adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand, product momentum and a broad innovation and M&A pipeline. However, these positives were offset by a meaningful hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply constraints and reduced full-year guidance. Management expressed confidence in the long-term outlook but acknowledged continued near-term uncertainty.View all MX:SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine

SYK Stock 12 Month Forecast
Average Price Target
$6,337.40
▲(15.14% Upside)
Technical Analysis
Integra Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Globus Medical
―











